Department of Microbiology and Immunology School of Medicine
Doina Ganea has not added Biography.
If you are Doina Ganea and would like to personalize this page please email our Author Liaison for assistance.
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.
Amino acids Dec, 2011 | Pubmed ID: 22139413
Inhibition of microglial CD40 expression by pituitary adenylate cyclase-activating polypeptide is mediated by interleukin-10.
Journal of neuroimmunology May, 2002 | Pubmed ID: 12020953
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists , 2002 | Pubmed ID: 12090463
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Glia Aug, 2002 | Pubmed ID: 12112366
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Nov, 2002 | Pubmed ID: 12223451
Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor.
Experimental hematology Sep, 2002 | Pubmed ID: 12225791
VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells.
Journal of neuroimmunology Dec, 2002 | Pubmed ID: 12446011
Galanin down-regulates microglial tumor necrosis factor-alpha production by a post-transcriptional mechanism.
Journal of neuroimmunology Jan, 2003 | Pubmed ID: 12507772
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
Journal of leukocyte biology Jan, 2003 | Pubmed ID: 12525573
Vasoactive intestinal peptide inhibits IL-8 production in human monocytes.
Biochemical and biophysical research communications Feb, 2003 | Pubmed ID: 12589787
Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity.
Biochemical and biophysical research communications Mar, 2003 | Pubmed ID: 12604342
Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology May, 2003 | Pubmed ID: 12626429
The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
Current pharmaceutical design , 2003 | Pubmed ID: 12678866
PACAP in immunity and inflammation.
Annals of the New York Academy of Sciences May, 2003 | Pubmed ID: 12794054
Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Oct, 2003 | Pubmed ID: 12923064
Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells.
Journal of leukocyte biology Nov, 2003 | Pubmed ID: 12960284
Acute down-regulation of antibody production following spinal cord injury: role of systemic catecholamines.
Journal of neuropathology and experimental neurology Aug, 2003 | Pubmed ID: 14503640
Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells.
Cellular immunology Jun, 2003 | Pubmed ID: 14527510
VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Journal of leukocyte biology Jun, 2004 | Pubmed ID: 15020654
The significance of vasoactive intestinal peptide in immunomodulation.
Pharmacological reviews Jun, 2004 | Pubmed ID: 15169929
Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Aug, 2004 | Pubmed ID: 15180965
VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Sep, 2004 | Pubmed ID: 15231725
A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2.
The Journal of biological chemistry Dec, 2004 | Pubmed ID: 15498767
Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) Dec, 2004 | Pubmed ID: 15557192
Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.
Proceedings of the National Academy of Sciences of the United States of America Sep, 2005 | Pubmed ID: 16150720
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo.
Journal of leukocyte biology Dec, 2005 | Pubmed ID: 16204628
The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) Dec, 2005 | Pubmed ID: 16301637
Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors.
Journal of immunology (Baltimore, Md. : 1950) Jan, 2006 | Pubmed ID: 16365400
Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.
Blood May, 2006 | Pubmed ID: 16397128
Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis.
European journal of immunology Feb, 2006 | Pubmed ID: 16402407
Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response.
Blood May, 2006 | Pubmed ID: 16418327
Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease.
Proceedings of the National Academy of Sciences of the United States of America Mar, 2006 | Pubmed ID: 16537513
Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.
The American journal of pathology Apr, 2006 | Pubmed ID: 16565493
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation.
Annals of the New York Academy of Sciences Jul, 2006 | Pubmed ID: 16888164
Vasoactive intestinal polypeptide induces regulatory dendritic cells that prevent acute graft versus host disease and leukemia relapse after bone marrow transplantation.
Annals of the New York Academy of Sciences Jul, 2006 | Pubmed ID: 16888171
Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis.
Annals of the New York Academy of Sciences Jul, 2006 | Pubmed ID: 16888172
VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease.
Annals of the New York Academy of Sciences Jul, 2006 | Pubmed ID: 16888178
VIP protects Th2 cells by downregulating granzyme B expression.
Annals of the New York Academy of Sciences Jul, 2006 | Pubmed ID: 16888222
A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.
Peptides Sep, 2007 | Pubmed ID: 17462790
The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis.
Journal of immunology (Baltimore, Md. : 1950) Jun, 2007 | Pubmed ID: 17548652
Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis.
Arthritis and rheumatism Aug, 2007 | Pubmed ID: 17665454
Neuropeptides: active participants in regulation of immune responses in the CNS and periphery.
Brain, behavior, and immunity Jan, 2008 | Pubmed ID: 17706916
PGE2-induced metalloproteinase-9 is essential for dendritic cell migration.
Blood Jan, 2008 | Pubmed ID: 17925490
A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology Dec, 2006 | Pubmed ID: 18040812
In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells.
Journal of immunology (Baltimore, Md. : 1950) Jul, 2008 | Pubmed ID: 18566439
Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.
Brain, behavior, and immunity Nov, 2008 | Pubmed ID: 18598752
Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells.
Journal of immunology (Baltimore, Md. : 1950) Oct, 2008 | Pubmed ID: 18802056
Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury.
Clinical neurosurgery , 2008 | Pubmed ID: 19248685
Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology Jun, 2009 | Pubmed ID: 19255856
CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury.
Microvascular research Jun, 2009 | Pubmed ID: 19332079
Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation.
Blood Aug, 2009 | Pubmed ID: 19531658
Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.
Molecular therapy : the journal of the American Society of Gene Therapy May, 2010 | Pubmed ID: 20068554
Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family.
Lipids in health and disease , 2010 | Pubmed ID: 20122166
IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9.
Journal of immunology (Baltimore, Md. : 1950) Apr, 2010 | Pubmed ID: 20190134
The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury.
Clinical neurosurgery , 2009 | Pubmed ID: 20214038
Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.
Current opinion in pharmacology Aug, 2010 | Pubmed ID: 20399708
Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis.
Brain, behavior, and immunity Jul, 2011 | Pubmed ID: 20854895
Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation.
Clinical lipidology Jun, 2011 | Pubmed ID: 21804863
Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation.
The Journal of biological chemistry Nov, 2011 | Pubmed ID: 21940623
Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.
Journal of neurotrauma Dec, 2011 | Pubmed ID: 21970496
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。